The in Medical Technology

Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership

- Program Focuses on Expanding Pipeline of Drugs For People with Type 1 Diabetes - NEW YORK, Aug. 5 /PRNewswire-USNewswire/ -- The Juvenile Diabetes Research Foundation said today that it has entered into a novel collaborative research agreement with the Genomics Institute of th...

2,500 Cases Completed With the Magnetic Irrigated Catheter

ST. LOUIS, Aug. 5 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS ), announced today that clinicians have performed more than 2,500 procedures with the magnetic irrigated catheter since its commercial release. The clinical performance of the catheter in ...

ARUP Laboratories Applauds FDA's Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer

SALT LAKE CITY, Aug. 4 /PRNewswire/ -- ARUP Laboratories , a national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, supports the U.S. Food and Drug Administration's (FDA) decision to put KRAS on the label of...

CTMM Becomes One of the World's Largest Public-Private Partnerships in Translational Medical Research

EINDHOVEN, The Netherlands, August 4 /PRNewswire/ -- With today's final approval of a research project into prostate cancer, the Dutch CTMM (Center for Translational Molecular Medicine) today announced the successful completion of 265 million euro funding for translational (bench-to-bedside) m...

Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

LAUSANNE, Switzerland and WOBURN, Massachusetts, August 4 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Mercury Therapeutics, Inc. (Mercury), a ...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

TITUSVILLE, N.J., Aug. 3 /PRNewswire/ -- The U.S. Food and Drug Administration approved INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults on Friday, July 31, 2009. It is the first ...

Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C

PRINCETON, N.J., July 31 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) reported today positive preliminary results from its phase I clinical trial of PSI-7851 for the treatment of hepatitis C (HCV). PSI-7851 is a second generation nucleotide polymerase inhib...

Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window

Findings May Potentially Lead to New Approach to Stroke Treatment BOCA RATON, Fla., July 30 /PRNewswire-USNewswire/ -- When minimally invasive endovascular (through the vessel) therapy made its debut two decades ago, stroke care underwent a major shift as the "window of treatmen...

FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents

PHILADELPHIA, July 28 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company, announces that it has received a Complete Response letter today for INTUNIV(TM) (guanfacine) Extended Release from the Food and Drug Administration (FDA). Thi...

Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms

COLLEGEVILLE, Pa., July 27 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), announced the publication in Fertility and Sterility of data from a Phase 3 clinical study that showed that the investigational compound bazedoxifene/conjugated estrogens...

Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)

DEERFIELD, Ill., July 22, and OSAKA, Japan, July 23 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, received notification from the U.S. Food and Drug ...

Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma

KENILWORTH, N.J., July 22 /PRNewswire-FirstCall/ -- Schering-Plough today announced that a New Drug Application (NDA) for a fixed-dose combination of mometasone furoate and formoterol fumarate has been filed in the United States and accepted for review by the U.S. Food and Drug Administration...

Awardees for the 2009 Young Investigator Grant for Probiotics Research Announced

ALEXANDRIA, Va., July 21 /PRNewswire/ -- The Global Probiotics Council (GPC), a committee established in 2004 by DANONE and Yakult Honsha Co., Ltd., announced the two recipients of the annual Young Investigator Grant for Probiotics Research (YIGPRO) today. The program was created to identify ...

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations

LAUSANNE, Switzerland, July 21 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that the Swiss agency for therapeutic products, Swissme...

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations

LAUSANNE, Switzerland, July 21 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that the Swiss agency for therapeutic products, Swissme...

Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has successfully completed a three-day...

Teeth and Gums Also Benefit from the Healing Power of Aloe Vera

CHICAGO, July 20 /PRNewswire-USNewswire/ -- The aloe vera plant has a long history of healing power. Its ability to heal burns and cuts and soothe pain has been documented as far back as the 10th century. Recently, aloe vera has gained some popularity as an active ingredient in toot...

International Journal of Occupational and Environmental Health Features Discovery of Asbestos-Related Pain Origin from Scientists at the Karmanos Cancer Institute in Detroit

DETROIT, July 20 /PRNewswire-USNewswire/ -- Scientists at the Barbara Ann Karmanos Cancer Institute's National Center for Vermiculite and Asbestos-Related Cancers (NCVAC) have discovered a probable reason for the unrelenting chest pain experienced in certain patients with asbestos-r...

Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharma's Product Class

SAN DIEGO, July 13 /PRNewswire/ -- Research published in the June 26, 2009 edition of Proceedings of National Academy of Sciences provides further evidence for novel roles of tRNA synthetases in disease, validating the therapeutic potential for aTyr Pharma's new class of naturally occurring prot...

Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer

MARSEILLE, France, July 10 /PRNewswire-FirstCall/ -- Ipsogen SA (Alternext: ALIPS) today reported that the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer indicated for the first time that the Genomic Grade could be considered as an adjunct to the histolo...

ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients

KENILWORTH, N.J., July 9 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for ASMANEX TWISTHALER (mometasone furoate dry powder inhaler) for the treatment of bro...

Dry Mouth Linked to Prescription and Over the Counter Drugs

BALTIMORE, July 9 /PRNewswire-USNewswire/ -- Approximately ninety-one percent of dentists say patients complaining about dry mouth are taking multiple medications, according to a nationwide member survey conducted by the Academy of General Dentistry (AGD). Dry mouth, or xerostomia , is caused by...

Why Do African-Americans Fare Worse With Cancer? Access and Economics Are Only Part of the Story

ANN ARBOR, Mich., July 7 /PRNewswire-USNewswire/ -- An analysis of almost 20,000 patient records from the Southwest Oncology Group's database of clinical trials finds, for the first time, that African-American breast, ovarian, and prostate cancer patients tend to die earlier than patients of oth...

Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet

LONDON, July 7 /PRNewswire/ -- The final analysis of the largest efficacy trial of a cervical cancer vaccine is published today in The Lancet . The study, involving 18,644 women, confirmed GlaxoSmithKline's Cervarix (R) is highly effective at protecting against the two most common cervical cance...

Number of Patients With Dementia on the Rise

ANN ARBOR, Mich., July 6 /PRNewswire-USNewswire/ -- At 81, Alberta Sabin's mind is not as sharp as it used to be, and she knows it. She frequently misplaces common items, forgets names and appointments, some of the most frustrating aspects of memory loss, she says. "I had been looking fo...

Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value

TOKYO and WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical development pr...

Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder

FRAZER, Pa., June 30 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH ) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval of NUVIGIL(R) (armodafinil) Tablets [C-IV] for the indication of impro...

Sanofi-aventis Stands Behind the Safety of Lantus(R)

BRIDGEWATER, N.J., June 26 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ) has just been made aware of data associated with a retrospective follow-up of four patient registries. The results of these data clearly show that no definitive conclusions can be drawn regarding...

Acute Lymphoblastic Leukemia, the Most Common Childhood Cancer, Is Curable Without Preventive Cranial Radiation

St. Jude study shows personalized chemotherapy can improve cure rate and avoid the use of radiation in acute lymphoblastic leukemia treatment MEMPHIS, Tenn., June 24 /PRNewswire-USNewswire/ -- Childhood acute lymphoblastic leukemia (ALL) can be successfully treated using a carefully person...

Infant Formula Company Teams With the University of Virginia Pediatrics Department to Conduct Clinical Studies

GORDONSVILLE, Va., June 24 /PRNewswire/ -- PBM Products, LLC, a leading infant formula company that supplies store-brand infant formulas to Walmart, Sam's Club, Target, Kroger, CVS, Walgreens, and other retailers, has partnered with the University of Virginia (U.Va.) to conduct clinical studies ...

Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis

SAN DIEGO, June 24 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a second Phase 2 clinical trial with a novel drug candidate for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection. The trial will enroll patients for whom treatment with...

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease

- FDA Agreement Reached on Phase 3 Study Design, Primary Endpoint and Histological Methodology - CRANBURY, N.J., June 22 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD ) today announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal...

Clinical and Histopathological Results Using Pollogen's TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy

TEL AVIV, Israel, June 17 /PRNewswire/ -- A recent clinical study using Pollogen's regen(TM) device- the latest aesthetic solution powered by 3rd generation TriPollar(TM) technology, confirms the safety and efficacy of TriPollar(TM) technology in reducing fat and collagen remodeling. The peer ...

Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia

PALO ALTO, Calif., June 15 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals' (Nasdaq: JAZZ ) sodium oxybate (JZP-6) demonstrated statistically significant and clinically meaningful improvement in pain and the core symptoms associated with fibromyalgia, according to Phase III data presented last we...

Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome

Findings Published in Nature Medicine Suggest Broad Implications for the Treatment of Inflammatory and Autoimmune Disorders SOUTH SAN FRANCISCO, Calif., June 15 /PRNewswire/ -- Proteolix, Inc. announced that in an article published today in Nature Medicine, Proteolix's selective immunoprote...

When It Comes to Natural Remedies for Hormonal Balance, the Proof Is in the Clinical Research

Femmenessence: Proven to Regulate Hormone Levels in Women SAN FRANCISCO, June 12 /PRNewswire/ -- Women approaching and exiting menopause are in a bind. As hormone levels fluctuate and decline, they experience a range of uncomfortable symptoms that can include hot flashes, night sweats, mood d...

Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System

New Capabilities Will Further Extend GeneXpert System Technology Advantages SUNNYVALE, Calif., June 10 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD ) today announced that it has received a notice of grant award from the National Institute of Allergy and Infectious Diseases to develop new...

Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009

JERUSALEM, June 10 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of oral delivery systems, announced that Oramed was chosen to present at the 8th National Life Science & Technology Week ILSI-BIOMED Conference, Israel 2009. Th...

Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily

Data Findings Published in June Issue of Circulation SILVER SPRING, Md. and INDIANAPOLIS, June 9 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR ) and Eli Lilly and Company (NYSE: LLY ) today announced the results of a pivotal 16-week study showing that a once-dail...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

PRINCETON, N.J., June 9 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that it has received Protocol Assistance feedback from the European Medicines Agency (EMEA) on the design of its confirmato...